

A novel Cdk9 inhibitor preferentially targets tumor cell

Oncotarget

5, 375-385

DOI: [10.18632/oncotarget.1568](https://doi.org/10.18632/oncotarget.1568)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73. <i>Oncotarget</i> , 2014, 5, 7691-7704.	0.8	48
2	Bay 61-3606 Sensitizes TRAIL-Induced Apoptosis by Downregulating Mcl-1 in Breast Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0146073.	1.1	19
3	CDK8 kinase—An emerging target in targeted cancer therapy. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 1617-1629.	1.1	56
4	Targeting cell cycle regulators in hematologic malignancies. <i>Frontiers in Cell and Developmental Biology</i> , 2015, 3, 16.	1.8	93
5	The history and future of targeting cyclin-dependent kinases in cancer therapy. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 130-146.	21.5	1,316
6	Modifications of RNA polymerase II CTD: Connections to the histone code and cellular function. <i>Biotechnology Advances</i> , 2015, 33, 856-872.	6.0	34
7	Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors. <i>Cancers</i> , 2015, 7, 179-237.	1.7	257
8	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 – 2014). <i>Expert Opinion on Therapeutic Patents</i> , 2015, 25, 953-970.	2.4	38
9	Cyclic Dependent Kinase (CDK): Role in Cancer Pathogenesis and as Drug Target in Cancer Therapeutics. <i>Journal of Cancer Science & Therapy</i> , 2016, 8, .	1.7	9
10	Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells. <i>Acta Pharmacologica Sinica</i> , 2016, 37, 1481-1489.	2.8	30
11	Targeting CDK9: a promising therapeutic opportunity in prostate cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, T211-T226.	1.6	57
12	Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents. <i>Future Medicinal Chemistry</i> , 2016, 8, 2047-2076.	1.1	10
13	Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. <i>Cancer Biology and Therapy</i> , 2016, 17, 769-777.	1.5	17
14	Overview of CDK9 as a target in cancer research. <i>Cell Cycle</i> , 2016, 15, 519-527.	1.3	156
15	Molecular principle of the cyclin-dependent kinase selectivity of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile derivatives revealed by molecular modeling studies. <i>Physical Chemistry Chemical Physics</i> , 2016, 18, 2034-2046.	1.3	21
16	Highly Potent, Selective, and Orally Bioavailable 4-Thiazol- <i>N</i> -(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1892-1915.	2.9	55
17	Inhibitors of cyclin-dependent kinases as cancer therapeutics. , 2017, 173, 83-105.		278
18	Targeting Cyclin-Dependent Kinases in Ovarian Cancer. <i>Cancer Investigation</i> , 2017, 35, 367-376.	0.6	20

#	ARTICLE	IF	CITATIONS
19	Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. <i>Cell Reports</i> , 2017, 20, 2833-2845.	2.9	40
20	Cyclin-dependent kinase 9 is required for the survival of adult <i>Drosophila melanogaster</i> glia. <i>Scientific Reports</i> , 2017, 7, 6796.	1.6	4
21	Inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin in hypopharyngeal carcinoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2017, 482, 536-541.	1.0	7
22	Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 427-441.	1.1	15
23	Transcriptional targeting of oncogene addiction in medullary thyroid cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	19
24	Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia. <i>Oncotarget</i> , 2018, 9, 26353-26369.	0.8	5
25	Combined protein and ligand based physicochemical aspects of molecular recognition for the discovery of CDK9 inhibitor. <i>Gene Reports</i> , 2018, 13, 212-219.	0.4	6
26	Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carboxamide (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor. <i>European Journal of Medicinal Chemistry</i> , 2018, 158, 896-916.	2.6	32
27	Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma. <i>Haematologica</i> , 2018, 103, 2059-2068.	1.7	14
28	CDK9 inhibitors in acute myeloid leukemia. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 36.	3.5	110
29	Targeting CDK9 for treatment of colorectal cancer. <i>Molecular Oncology</i> , 2019, 13, 2178-2193.	2.1	39
30	Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986485.	1.4	11
31	CDK8 Regulates Insulin Secretion and Mediates Postnatal and Stress-Induced Expression of Neuropeptides in Pancreatic β^2 Cells. <i>Cell Reports</i> , 2019, 28, 2892-2904.e7.	2.9	13
32	Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer. <i>FASEB Journal</i> , 2019, 33, 5990-6000.	0.2	47
33	CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia. <i>Investigational New Drugs</i> , 2019, 37, 625-635.	1.2	26
34	EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma. <i>Haematologica</i> , 2020, 105, 1021-1031.	1.7	6
35	Antitumor activity, multitarget mechanisms, and molecular docking studies of quinazoline derivatives based on a benzenesulfonamide scaffold: Cell cycle analysis. <i>Bioorganic Chemistry</i> , 2020, 104, 104345.	2.0	15
36	Combined Inhibition of Epigenetic Readers and Transcription Initiation Targets the EWS-ETS Transcriptional Program in Ewing Sarcoma. <i>Cancers</i> , 2020, 12, 304.	1.7	13

#	ARTICLE	IF	CITATIONS
37	Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 693-706.	2.5	17
38	Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents. <i>European Journal of Medicinal Chemistry</i> , 2021, 214, 113244.	2.6	10
39	Targeting CDK9 for Anti-Cancer Therapeutics. <i>Cancers</i> , 2021, 13, 2181.	1.7	56
40	CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents. <i>Frontiers in Oncology</i> , 2021, 11, 678559.	1.3	62
41	Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising Approaches. <i>Cancers</i> , 2021, 13, 2497.	1.7	12
42	Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story. <i>Current Chemical Biology</i> , 2021, 15, 139-162.	0.2	0
43	Synthesis and biological evaluation of seliciclib derivatives as potent and selective CDK9 inhibitors for prostate cancer therapy. <i>Monatshefte für Chemie</i> , 2021, 152, 109-120.	0.9	3
44	Synthesis and biological evaluation of selected 7-azaindole derivatives as CDK9/Cyclin T and Haspin inhibitors. <i>Medicinal Chemistry Research</i> , 2020, 29, 1449-1462.	1.1	9
46	Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. <i>PLoS ONE</i> , 2015, 10, e0143685.	1.1	32
47	Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer. <i>Oncotarget</i> , 2016, 7, 56864-56875.	0.8	53
48	Tumor suppressor XAF1 induces apoptosis, inhibits angiogenesis and inhibits tumor growth in hepatocellular carcinoma. <i>Oncotarget</i> , 2014, 5, 5403-5415.	0.8	51
49	The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias. <i>Oncotarget</i> , 2014, 5, 12635-12645.	0.8	9
50	Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer. <i>Oncotarget</i> , 2015, 6, 14926-14939.	0.8	52
51	CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression. <i>Oncotarget</i> , 2016, 7, 9069-9083.	0.8	38
52	Phenylamino-pyrimidine (PAP) Privileged Structure: Synthesis and Medicinal Applications. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 227-243.	1.0	7
53	Targeting CDK9: A novel biomarker in the treatment of endometrial cancer. <i>Oncology Reports</i> , 2020, 44, 1929-1938.	1.2	13
55	The Renaissance of Cyclin Dependent Kinase Inhibitors. <i>Cancers</i> , 2022, 14, 293.	1.7	27
56	CDK9 is up-regulated and associated with prognosis in patients with papillary thyroid carcinoma. <i>Medicine (United States)</i> , 2022, 101, e28309.	0.4	3

#	ARTICLE	IF	CITATIONS
57	Metabolomics-based phenotypic screens for evaluation of drug synergy via direct-infusion mass spectrometry. <i>IScience</i> , 2022, 25, 104221.	1.9	8
58	CDK9 inhibitors in cancer research. <i>RSC Medicinal Chemistry</i> , 2022, 13, 688-710.	1.7	10
59	Molecular Insights on Selective and Specific Inhibitors of Cyclin Dependent Kinase 9 Enzyme (CDK9) for the Purpose of Cancer Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2023, 23, 383-403.	0.9	2
60	Design, synthesis, and biological evaluation of (E)-N ² -substitute-4-((4-pyridylpyrimidin-2-yl)amino)benzohydrazide derivatives as novel potential CDK9 inhibitors. <i>Arabian Journal of Chemistry</i> , 2022, 15, 104039.	2.3	4
61	Synthesis and Biological Evaluation of Imadazo[1,2-a]pyrazines as Anticancer and Antiviral Agents through Inhibition of CDK9 and Human Coronavirus. <i>Pharmaceuticals</i> , 2022, 15, 859.	1.7	3
62	Computational Investigations of Coumarin Derivatives as Cyclindependent Kinase 9 Inhibitors Using 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation. <i>Current Computer-Aided Drug Design</i> , 2022, 18, 363-380.	0.8	1
63	LS-007 inhibits melanoma growth via inducing apoptosis and cell cycle arrest and regulating macrophage polarization. <i>Melanoma Research</i> , 0, Publish Ahead of Print, .	0.6	0
64	Discovery of Novel and Potent Inhibitors of Cyclin-Dependent Kinases 7 and 9: Design, Synthesis, Structure-Activity Relationship Analysis and Biological Evaluation. <i>ChemMedChem</i> , 0, , .	1.6	3
65	Nature-Derived Compounds as Potential Bioactive Leads against CDK9-Induced Cancer: Computational and Network Pharmacology Approaches. <i>Processes</i> , 2022, 10, 2512.	1.3	1
66	Synthesis, Cytotoxic Evaluation, and Structure-Activity Relationship of Substituted Quinazolinones as Cyclin-Dependent Kinase 9 Inhibitors. <i>Molecules</i> , 2023, 28, 120.	1.7	2
67	CDK regulators-Cell cycle progression or apoptosis-Scenarios in normal cells and cancerous cells. <i>Advances in Protein Chemistry and Structural Biology</i> , 2023, , 125-177.	1.0	9
68	Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting. <i>Advances in Protein Chemistry and Structural Biology</i> , 2023, , 21-55.	1.0	6
69	CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma. <i>Molecular Cancer</i> , 2023, 22, .	7.9	5